CN113274471A - Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application - Google Patents

Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application Download PDF

Info

Publication number
CN113274471A
CN113274471A CN202110477676.XA CN202110477676A CN113274471A CN 113274471 A CN113274471 A CN 113274471A CN 202110477676 A CN202110477676 A CN 202110477676A CN 113274471 A CN113274471 A CN 113274471A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
traditional chinese
cerebrovascular diseases
treating cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110477676.XA
Other languages
Chinese (zh)
Inventor
宋银枝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110477676.XA priority Critical patent/CN113274471A/en
Publication of CN113274471A publication Critical patent/CN113274471A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
    • A61K36/835—Aquilaria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9064—Amomum, e.g. round cardamom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, a preparation method, a use method and application thereof, wherein the pharmaceutical composition of the pharmaceutical composition is a medicament prepared from nine traditional Chinese medicines, namely salvia miltiorrhiza, fructus amomi, agilawood, snakegourd fruit, allium macrostemon, rhizoma pinellinae praeparata, immature bitter orange, rhodiola rosea and pseudo-ginseng, and the traditional Chinese medicines are prepared from the following raw materials in parts by weight: 10-40 parts of salvia miltiorrhiza, 5-20 parts of fructus amomi, 5-20 parts of agilawood, 15-60 parts of snakegourd fruit, 5-20 parts of allium macrostemon, 5-20 parts of rhizoma pinellinae praeparata, 5-20 parts of immature bitter orange, 5-20 parts of rhodiola rosea and 5-20 parts of pseudo-ginseng. The invention has the characteristics of reasonable compatibility, simple materials, easy acquisition and definite curative effect, has the effects of reducing phlegm, descending turbidity, relieving chest stuffiness, activating blood circulation and dredging collaterals, is suitable for daily conditioning of patients with symptoms of palpitation and chest stuffiness, dizziness, nervousness, sleepiness, phlegm-dampness stagnation, qi stagnation, blood stasis and the like, and is used for preventing and treating cardiovascular and cerebrovascular diseases.

Description

Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application
Technical Field
The invention relates to the field of traditional Chinese medicine preparations, in particular to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, a preparation method, a use method and application thereof.
Background
With the change of life style of people and the change of social environment, cardiovascular risk factors are continuously increased, the morbidity and mortality of cardiovascular diseases such as hypertension, coronary heart disease, atherosclerosis and the like in China are in an increasing stage, and the structure of the attack age is gradually younger. The data show that the cardiovascular disease mortality rate of China is the top, higher than that of tumors and other diseases, and the cardiovascular disease mortality rate of urban and rural residents in China keeps on rising trend. The total hospitalization cost of cardiovascular and cerebrovascular diseases is rapidly increased, and the annual speed increase is much higher than the national production total value increase in 2004 to the present. The burden of cardiovascular diseases in China is gradually increased, which becomes a great public health problem and the prevention and treatment of cardiovascular diseases are not easy.
At present, the method of combining traditional Chinese medicine with Chinese and western medicine is a trend of preventing and treating cardiovascular diseases in recent years, and the traditional Chinese medicine for treating cardiovascular diseases in China mainly takes syndrome differentiation and overall treatment as principles in long-term practice, and forms a series of effective formulas and Chinese patent medicines. In clinical treatment, the Chinese patent medicine for treating cardiovascular diseases has the following advantages: can be used in various links of disease treatment starting from integral adjustment. The traditional Chinese medicine composition has the effects of treating the symptoms of the disease in an urgent way and treating the root cause of the disease in a slow way, has the advantages of fixed dosage form, clear drug effect, stable curative effect, more target spots, less side effect and the like, is suitable for long-term rehabilitation after operation in the aspect of use, has relatively low cost, and can reduce the economic burden of patients to a great extent. The development of formulations in this respect is advantageous for meeting clinical therapeutic needs.
Modern medical means such as 'coronary endovascular stents, cerebrovascular stents, balloon dilatation of peripheral vessels' can solve the physical stenosis of some operable vessels and reduce some vascular events; anticoagulation, lipid regulation and other treatments also have certain blood vessel protection effects, but the methods for preventing and treating microangiopathy and repairing endothelial injury are few. Therefore, the traditional Chinese medicine formula with the functions of improving microcirculation and tube endothelium is searched for and invented by ancient training, collecting and collecting the prescriptions.
Disclosure of Invention
The invention mainly aims to provide a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, a preparation method, a use method and application thereof, and aims to provide a solution for treating cardiovascular and cerebrovascular diseases by resolving phlegm-blood stasis and reducing phlegm and turbidity, and activating blood and dredging collaterals for patients with phlegm-blood stasis.
In order to achieve the purpose, the invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, which is a medicament prepared from nine traditional Chinese medicines including salvia miltiorrhiza, fructus amomi, agilawood, trichosanthes kirilowii maxim, allium macrostemon, rhizoma pinellinae praeparata, immature bitter orange, rhodiola rosea and pseudo-ginseng, and the traditional Chinese medicines are prepared from the following raw materials in parts by weight: 10-40 parts of salvia miltiorrhiza, 5-20 parts of fructus amomi, 5-20 parts of agilawood, 15-60 parts of snakegourd fruit, 5-20 parts of allium macrostemon, 5-20 parts of rhizoma pinellinae praeparata, 5-20 parts of immature bitter orange, 5-20 parts of rhodiola rosea and 5-20 parts of pseudo-ginseng.
Optionally, the traditional Chinese medicines comprise the following components in parts by weight: 20-35 parts of salvia miltiorrhiza, 8-15 parts of fructus amomi, 8-15 parts of agilawood, 25-45 parts of snakegourd fruit, 8-15 parts of allium macrostemon, 8-15 parts of rhizoma pinellinae praeparata, 8-15 parts of immature bitter orange, 8-15 parts of rhodiola rosea and 8-15 parts of pseudo-ginseng.
Optionally, the optimal mixture ratio of the traditional Chinese medicines in parts by weight is as follows: 25 parts of salvia miltiorrhiza, 12 parts of fructus amomi, 12 parts of agilawood, 37 parts of snakegourd fruit, 12 parts of allium macrostemon, 12 parts of rhizoma pinellinae praeparata, 10 parts of immature bitter orange, 10 parts of rhodiola rosea and 11 parts of pseudo-ginseng.
Optionally, the weight portion is a weight measurement unit of gram, two, jin or kg.
Optionally, the dosage form of the pharmaceutical composition is pills or powder.
Optionally, the dosage form of the pharmaceutical composition is a pellet, a tablet, a granule or a capsule.
In order to achieve the above object, the present invention further provides a preparation method of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, the preparation method comprising:
(1) weighing the nine traditional Chinese medicines in parts by weight;
(2) cleaning the nine traditional Chinese medicines, removing impurities, drying, mixing, crushing, sieving, sterilizing, forming pills or powder and packaging to form the pills or powder of the pharmaceutical composition.
In order to achieve the above object, the present invention further provides a preparation method of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, the preparation method comprising:
(1) weighing the nine traditional Chinese medicines in parts by weight;
(2) cleaning, slicing and mixing the nine traditional Chinese medicines, adding water into the mixed nine traditional Chinese medicines, and adding 1120-2000 parts by weight of purified water;
(3) decocting the nine traditional Chinese medicines with water, decocting with big fire for 20-60 minutes, decocting with small fire for 20-60 minutes, filtering to remove residues, decocting the residues with 610-1100 parts by weight of pure water for 30-90 minutes, filtering to remove residues; mixing the first and second medicinal liquids, adding conventional adjuvants, and making into clinically acceptable tablet, granule, pill or capsule.
To achieve the above object, the present invention also provides a method for using the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases as described above, the method comprising:
after the pharmaceutical composition is formed into pills or powder, the pharmaceutical composition is orally taken for 2-3 times a day, and 8g to 10g of the pharmaceutical composition is orally taken each time.
In order to achieve the above object, the present invention also provides a use of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to the above, for preventing and treating coronary heart disease, arteriosclerosis, palpitation, syndrome X, and perimenopausal syndrome.
The traditional Chinese medicine formula of the medicinal composition is named as Danxiang Tongmai pill, and is mainly used for preventing and treating cardiovascular and cerebrovascular disease microangiopathy and repairing endothelial injury, the traditional Chinese medicine formula of the invention is simple and convenient, raw materials are easily available, the cost is low, the taking is convenient, the patient acceptance is high, the curative effect is practical and reliable, the diseases such as coronary heart disease, arteriosclerosis, palpitation, X syndrome, perimenopausal syndrome and the like caused by unsmooth qi activity, phlegm stagnation and blood stasis, vein stagnation and emotional disorder are remarkably improved, the curative effect is improved, and the effective rate is more than 90%.
In one embodiment, the pharmaceutical composition prepared by the traditional Chinese medicine formula of the invention is a medicament prepared from nine traditional Chinese medicines, namely salvia miltiorrhiza, fructus amomi, agilawood, snakegourd fruit, allium macrostemon, rhizoma pinellinae praeparata, immature bitter orange, rhodiola rosea and pseudo-ginseng, wherein the traditional Chinese medicines comprise the following components in parts by weight: 10-40 g/part of salvia miltiorrhiza, 5-20 g/part of fructus amomi, 5-20 g/part of agilawood, 15-60 g/part of snakegourd fruit, 5-20 g/part of allium macrostemon, 5-20 g/part of rhizoma pinellinae praeparata, 5-20 g/part of immature bitter orange, 5-20 g/part of rhodiola rosea and 5-20 g/part of pseudo-ginseng.
In the traditional Chinese medicine formula of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, the salvia miltiorrhiza and the snakegourd fruit are mainly used as monarch drugs to promote blood circulation to remove blood stasis, widen the chest and reduce phlegm; however, the circulation of blood depends on the promotion of qi, if qi fails to circulate, blood fails to circulate once, and qi fails to circulate once, so that the compatibility of eaglewood, villous amomum fruit and longstamen onion bulb can warm the middle-jiao, promote qi circulation and relieve pain, and the rhizoma pinellinae praeparata, immature bitter orange, fructus aurantii immaturus, phlegm reduction, turbid turbidity reduction, rhodiola rosea and pseudo-ginseng can promote blood circulation, remove blood stasis and dredge vessels, which are used as assistant and guide. Gua Lou, Xie Bai and Fa Xia are the middle energizer meridian recipes for eliminating phlegm, resolving turbidity and widening chest, and have the effect of eliminating phlegm and descending turbidity. The traditional Chinese medicine formula of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases has the effects of promoting blood circulation, removing blood stasis, relieving chest stuffiness, reducing phlegm, descending turbid and dredging collaterals.
Detailed Description
All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
To better understand the advantages and differences of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases of the present invention, the following brief introduction presents the development background of the pharmaceutical composition of the present invention by the applicant:
the typical Chinese patent medicines for clinically treating cardiovascular diseases comprise: compound red sage root tablet, ginkgo leaf capsule, musk heart-protecting pill, heart-activating collateral capsule, xuesaitong tablet, heart-stabilizing granule, xuemaitong capsule and the like.
(1) The compound Saviae Miltiorrhizae radix tablet mainly comprises Saviae Miltiorrhizae radix, Notoginseng radix total saponin and Borneolum, has effects of promoting blood circulation for removing blood stasis, regulating qi-flowing for relieving pain, and can be used for treating thoracic obstruction due to qi stagnation and blood stasis with symptoms of chest distress and precordial stabbing pain; coronary heart disease and angina pectoris with the above syndrome.
(2) The folium Ginkgo capsule mainly comprises folium Ginkgo extract, has effects of promoting blood circulation, removing blood stasis, and dredging collaterals, and can be used for treating thoracic obstruction, cardialgia, apoplexy, hemiplegia, and stiff tongue due to blood stasis and obstruction of collaterals; coronary heart disease stable angina pectoris, cerebral infarction and the above syndromes.
(3) The musk heart-protecting pill mainly comprises artificial musk, ginseng extract, artificial bezoar, cinnamon, storax, toad venom and borneol, has the effects of aromatic warmness, qi tonifying and heart strengthening, and is used for treating thoracic obstruction caused by qi stagnation and blood stasis, with the symptoms of precordial pain and immobility; angina pectoris and myocardial infarction due to myocardial ischemia.
(4) The capsule mainly comprises ginseng, leech, scorpion, red paeony root, cicada slough, ground beeltle, centipede, sandalwood, dalbergia wood, frankincense (prepared), spina date seed (fried) and borneol, has the effects of tonifying qi, activating blood circulation and dredging collaterals and relieving pain, and is mainly used for treating coronary heart disease and angina, heart qi deficiency, blood stasis and collateral obstruction, and symptoms of chest distress, pricking pain, angina, immobility, palpitation, spontaneous perspiration, shortness of breath and hypodynamia, purple dark tongue or ecchymosis, and thready and unsmooth pulse or intermittent pulse.
(5) The composition of the tablet for treating the blood stasis is the panax notoginseng saponins, has the effects of activating blood circulation to dissipate blood stasis, dredging collaterals and activating collaterals, inhibiting platelet aggregation and increasing cerebral blood flow, and is used for treating cerebral collateral stasis, apoplexy hemiplegia, heart vessel stasis, thoracic obstruction and cardiodynia; sequelae of cerebrovascular disease, coronary heart disease and angina pectoris are the above symptoms.
(6) The heart stabilizing granules are prepared from radix codonopsis pilosulae, rhizoma polygonati, pseudo-ginseng, amber and nardostachys chinensis, have the effects of tonifying qi and yin, and promoting blood circulation to remove blood stasis, and are mainly used for treating palpitation, shortness of breath, hypodynamia, chest distress and chest pain caused by deficiency of both qi and yin and stasis of heart vessels; ventricular premature beat and atrial premature beat with the above syndromes.
(7) The capsule comprises clavus, radix Salviae Miltiorrhizae, rhizoma Chuanxiong, radix Puerariae, fructus Gardeniae, rhizoma Alismatis, and ramulus Cinnamomi, has effects of promoting blood circulation and removing blood stasis, and can be used for treating thoracic obstruction, chest distress, chest pain, and palpitation caused by blood stasis obstruction; and coronary heart disease and angina pectoris.
In summary, although many Chinese patent medicines for treating cardiovascular diseases have many varieties, most of the effects are focused on promoting blood circulation, removing blood stasis and dredging collaterals, and a small part of the Chinese patent medicines have the effects of tonifying qi, activating blood or nourishing yin, the traditional Chinese patent medicines for treating cardiovascular diseases have the effects of reducing phlegm, lowering turbidity, promoting blood circulation and dredging collaterals and are rarely used for treating patients with intermingled phlegm and blood stasis and phlegm and blood stasis internal resistance.
The traditional Chinese medicine formula (Danxiang pulse-activating pill) of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases integrates the advantages of all the formulas, not only can reduce phlegm and turbid pathogen and relieve chest stuffiness, but also has the effects of activating blood and activating pulse, is suitable for daily conditioning of patients with symptoms of palpitation and chest stuffiness, dizziness, cloudiness, drowsiness, phlegm-dampness stagnation, qi stagnation, blood stasis and the like, and is different from other Chinese patent medicines on the market in China. The traditional Chinese medicine formula of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases is an empirical formula of Song Yinchu chief physicians in the cardiovascular disease department in Bao's traditional Chinese medicine hospital, is a protocol formula of the Bao's traditional Chinese medicine hospital for preventing and treating coronary heart disease, syndrome X and arteriosclerosis, is clinically applied for more than 20 years, and has a remarkable curative effect.
The prescription of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases is used for preventing and treating cardiovascular diseases such as coronary heart disease, atherosclerosis and the like, has definite curative effect, is convenient for patients to carry and improves the characteristics that the traditional Chinese medicine is complicated in decoction process and is not beneficial to modern urban people in order to ensure the medicine quality, promotes the modernization process of the traditional Chinese medicine, and can be developed into powder and pills to form the treatment characteristics.
The formula of the traditional Chinese medicine formula of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases comprises the following components:
the medicine composition is a medicament prepared from nine traditional Chinese medicines, namely salvia miltiorrhiza, fructus amomi, agilawood, snakegourd fruit, allium macrostemon, rhizoma pinellinae praeparata, immature bitter orange, rhodiola rosea and pseudo-ginseng;
the traditional Chinese medicine comprises the following components in parts by weight: 10-40 parts of salvia miltiorrhiza, 5-20 parts of fructus amomi, 5-20 parts of agilawood, 15-60 parts of snakegourd fruit, 5-20 parts of allium macrostemon, 5-20 parts of rhizoma pinellinae praeparata, 5-20 parts of immature bitter orange, 5-20 parts of rhodiola rosea and 5-20 parts of pseudo-ginseng.
In a preferred embodiment, the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases comprises the following traditional Chinese medicines in parts by weight: 20-35 parts of salvia miltiorrhiza, 8-15 parts of fructus amomi, 8-15 parts of agilawood, 25-45 parts of snakegourd fruit, 8-15 parts of allium macrostemon, 8-15 parts of rhizoma pinellinae praeparata, 8-15 parts of immature bitter orange, 8-15 parts of rhodiola rosea and 8-15 parts of pseudo-ginseng.
Specifically, the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases comprises the following traditional Chinese medicines in parts by weight: 25 parts of salvia miltiorrhiza, 12 parts of fructus amomi, 12 parts of agilawood, 37 parts of snakegourd fruit, 12 parts of allium macrostemon, 12 parts of rhizoma pinellinae praeparata, 10 parts of immature bitter orange, 10 parts of rhodiola rosea and 11 parts of pseudo-ginseng.
The pharmaceutical composition for treating cardiovascular and cerebrovascular diseases has the main functional indications that: promoting blood circulation, removing blood stasis, relieving chest stuffiness, eliminating phlegm, descending the turbid, and dredging collaterals. Can be used for preventing and treating coronary heart disease, arteriosclerosis, palpitation, syndrome X, and perimenopausal syndrome. The clinical symptoms comprise chest distress, chest pain, chest and hypochondrium swelling and distress, headache and fixed pain part, accompanied or not accompanied by symptoms of palpitation, shortness of breath, insomnia and the like. Pale purple or dark tongue with ecchymosis or sublingual varicose veins, white or greasy coating, wiry or unsmooth and slippery pulse. Has certain curative effect on other internal diseases with the symptoms of phlegm-stasis internal resistance.
The traditional Chinese medicine treatment theory of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases comprises the following steps: according to the traditional Chinese medicine, the heart governs blood vessels and governs mind, the brain is the house of essence and mind, and the syndrome and the characteristic of cardiovascular and cerebrovascular diseases are mainly manifested as blood vessel running disorder and mental activity abnormality. The common clinical causes are phlegm, stasis and deficiency. Extreme fire of five emotions, phlegm from fluid burning, or overeating fat, sweet, pungent and spicy food, phlegm turbidity in the interior, phlegm-fire disturbing the heart or obstructing the clear orifices, resulting in palpitation, insomnia, mania, etc.; or stagnation of blood due to emotional disorder, qi stagnation and blood stasis, or feeling cold pathogen, congealing cold and blood stasis, or yang qi deficiency due to chronic disease, and blood circulation weakness, which can cause palpitation, thoracic obstruction, and cardiodynia; or impairment of the aged and weak constitution, emotional, dietary and overstrain, which may lead to disturbance of qi and blood, obstruction of heart vessels and brain vessels, or obstruction of heart and brain by phlegm-stasis, resulting in sudden mental disorder or coma. In short, the main pathogenesis of this disease is phlegm-turbidity and blood stasis, heart blood stasis and damaged meridians. Therefore, aiming at pathogenesis, the medicine composition (Danxiang pulse-invigorating pill) of the invention is used for promoting blood circulation to remove blood stasis, relieving chest stuffiness and reducing phlegm, and descending turbid and invigorating pulse.
The prescription sources of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases of the invention are as follows:
one embodiment of the pharmaceutical composition, such as danxiang tongmai pills, is an empirical prescription of doctors in Song-Yizhi chief and ren-Shen of the department of cardiovascular diseases in Bao' an traditional Chinese medicine, is a prescription for preventing and treating hypertension, coronary heart disease and atherosclerosis, is clinically applied for more than 20 years, and has a remarkable curative effect.
Coronary heart disease, atherosclerosis and hypertension are common diseases of the cardiovascular disease department, wherein in the aspect of traditional Chinese medicine dialectical treatment, coronary heart disease is common in the symptoms of phlegm stagnation and blood stasis, qi deficiency and blood stasis and the like, and is common in clinic in Xuefu Zhuyu decoction, peach pit Chengqi decoction, trichosanthes kirilowii Maxim and allium macrostemon pinellia ternate decoction and the like, and common traditional Chinese medicines are astragalus, salvia miltiorrhiza, pseudo-ginseng and the like; atherosclerosis is usually manifested as phlegm-stasis obstructing the collaterals, and is clinically used in the treatment of turbid pathogen removing, blood fat reducing, diuresis inducing, dampness eliminating, blood circulation promoting and blood stasis removing, including Poria, Saviae Miltiorrhizae radix, Notoginseng radix, etc.
According to years of clinical experience, the pathogenesis of traditional Chinese medicine cardiovascular diseases such as atherosclerosis, hypertension, coronary heart disease and the like is mutually communicated, the traditional Chinese medicine pathogenesis is combination of internal and external pathogens and combination of deficiency and excess, most of internal pathogens are qi deficiency and spleen weakness, and phlegm turbidity is endogenous to qi movement and stasis; most of the external factors are phlegm-dampness blocking collaterals, collaterals stasis, phlegm turbidity clouding the mind, or stasis blocking heart vessels, so the pill is closely combined with clinic to provide the pill, and the pill and the snakegourd fruit are mainly used as monarch in the traditional Chinese medicine prescription of the pharmaceutical composition to promote blood circulation to remove blood stasis, widen chest and reduce phlegm; however, the circulation of blood depends on the promotion of qi, if qi fails to circulate, blood fails to circulate once, and qi fails to circulate once, so that the compatibility of eaglewood, villous amomum fruit and longstamen onion bulb can warm the middle-jiao, promote qi circulation and relieve pain, and the rhizoma pinellinae praeparata, immature bitter orange, fructus aurantii immaturus, phlegm reduction, turbid turbidity reduction, rhodiola rosea and pseudo-ginseng can promote blood circulation, remove blood stasis and dredge vessels, which are used as assistant and guide. Gua Lou, Xie Bai and Fa Xia are the middle energizer meridian recipes for eliminating phlegm, resolving turbidity and widening chest, and have the effect of eliminating phlegm and descending turbidity. The whole formula has the effects of promoting blood circulation to remove blood stasis, relieving chest stuffiness and reducing phlegm, descending turbid and dredging the pulse.
The salvia miltiorrhiza, the fructus amomi, the agilawood, the snakegourd fruit, the allium macrostemon, the rhizoma pinellinae praeparata, the immature bitter orange, the rhodiola rosea and the pseudo-ginseng in the traditional Chinese medicine prescription of the pharmaceutical composition are recorded in 2015 edition of Chinese pharmacopoeia. The prescription Chinese medicinal materials do not have eighteen antagonisms and nineteen incompatibilities of compatibility in toxic medicinal materials and traditional Chinese medicine theories recorded in medical toxic drug management methods, and the dosage of each medicinal material does not exceed the standard regulation.
The following 4 examples are provided to illustrate various aspects of the process for preparing the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to the present invention:
example 1
In the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, the raw material medicines used in the embodiment are 40.0 g of salvia miltiorrhiza, 20.0 g of fructus amomi, 20.0 g of agilawood, 60.0 g of snakegourd fruit, 20.0 g of allium macrostemon, 20.0 g of rhizoma pinellinae praeparata, 20.0 g of immature bitter orange, 20.0 g of rhodiola rosea and 20.0 g of pseudo-ginseng.
The preparation method (process) of the pill is adopted in the embodiment:
(1) weighing the nine traditional Chinese medicines according to the parts by weight, wherein the salvia miltiorrhiza is 40.0 g, the fructus amomi is 20.0 g, the agilawood is 20.0 g, the snakegourd fruit is 60.0 g, the allium macrostemon is 20.0 g, the rhizoma pinellinae praeparata is 20.0 g, the immature bitter orange is 20.0 g, the rhodiola rosea is 20.0 g and the pseudo-ginseng is 20.0 g;
(2) removing impurities from the nine traditional Chinese medicines respectively, drying, mixing, pulverizing, sieving, and sterilizing;
(3) and (3) adding a proper amount of honey into the mixture of the nine sterilized traditional Chinese medicines in the step (2), mixing, preparing pills, and packaging to form the pills of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases.
Example 2
In the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, the raw material medicines used in the embodiment are 10.0 g of salvia miltiorrhiza, 5.0 g of fructus amomi, 5.0 g of agilawood, 15.0 g of snakegourd fruit, 5.0 g of allium macrostemon, 5.0 g of rhizoma pinellinae praeparata, 5.0 g of immature bitter orange, 5.0 g of rhodiola rosea and 5.0 g of pseudo-ginseng.
The preparation method (process) of the pill is adopted in the embodiment:
(1) weighing the nine traditional Chinese medicines according to the parts by weight, wherein the red sage root is 10.0 g, the fructus amomi is 5.0 g, the agilawood is 5.0 g, the snakegourd fruit is 15.0 g, the allium macrostemon is 5.0 g, the rhizoma pinellinae praeparata is 5.0 g, the immature bitter orange is 5.0 g, the rhodiola rosea is 5.0 g and the pseudo-ginseng is 5.0 g;
(2) removing impurities from the nine traditional Chinese medicines respectively, drying, mixing, pulverizing, sieving, and sterilizing;
(3) and (3) adding a proper amount of honey into the mixture of the nine sterilized traditional Chinese medicines in the step (2), mixing, preparing pills, and packaging to form the pills of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases.
Example 3
In the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, the raw material medicines used in the embodiment are 25.0 g of salvia miltiorrhiza, 12.0 g of fructus amomi, 12.0 g of agilawood, 37.0 g of snakegourd fruit, 12.0 g of allium macrostemon, 12.0 g of rhizoma pinellinae praeparata, 10.0 g of immature bitter orange, 10.0 g of rhodiola rosea and 11.0 g of pseudo-ginseng.
The powder preparation method (process) is adopted in the embodiment:
(1) weighing the nine traditional Chinese medicines according to the parts by weight, wherein the red sage root is 25.0 g, the fructus amomi is 12.0 g, the agilawood is 12.0 g, the snakegourd fruit is 37.0 g, the allium macrostemon is 12.0 g, the rhizoma pinellinae praeparata is 12.0 g, the immature bitter orange is 10.0 g, the rhodiola rosea is 10.0 g and the pseudo-ginseng is 11.0 g;
(2) cleaning the nine traditional Chinese medicines, removing impurities, drying, mixing, crushing, sieving and sterilizing;
(3) packaging the mixture of the nine traditional Chinese medicines sterilized in the step (2) to prepare a packaging bag (which can be a gauze bag) of the powder, so as to form the powder of the pharmaceutical composition.
Example 4
In the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, the raw material medicines used in the embodiment are 20.0 g of salvia miltiorrhiza, 8.0 g of fructus amomi, 8.0 g of agilawood, 25.0 g of snakegourd fruit, 8.0 g of allium macrostemon, 8.0 g of rhizoma pinellinae praeparata, 8.0 g of immature bitter orange, 8.0 g of rhodiola rosea and 8.0 g of pseudo-ginseng.
The preparation method (process) of the present example:
(1) weighing the nine traditional Chinese medicines according to the parts by weight, wherein the red sage root is 20.0 g, the fructus amomi is 8.0 g, the agilawood is 8.0 g, the snakegourd fruit is 25.0 g, the allium macrostemon is 8.0 g, the rhizoma pinellinae praeparata is 8.0 g, the immature bitter orange is 8.0 g, the rhodiola rosea is 8.0 g and the pseudo-ginseng is 8.0 g;
(2) cleaning, slicing and mixing the nine traditional Chinese medicines, adding water into the mixed nine traditional Chinese medicines, and adding 1200 ml of purified water;
(3) decocting the nine traditional Chinese medicines with water, decocting with strong fire for 20-60 minutes, decocting with slow fire for 20-60 minutes, filtering to remove residue, decocting the residue with 650 ml of pure water for 30-90 minutes, and filtering to remove residue; mixing the first and second medicinal liquids, adding conventional adjuvants, and making into clinically acceptable dosage forms such as pill, tablet, granule or capsule.
The application proposes the use of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases:
(1) the dosage forms of powder, tablet, granule, capsule, pill, pellet, etc. are not more than 27 g of crude drug taken every day;
(2) the powder can be soaked in boiling water for administration, and is not limited as water for daily administration.
The application of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases is used for preventing and treating coronary heart disease, arteriosclerosis, palpitation, syndrome X and perimenopausal syndrome.
The therapeutic effect judgment standard is as follows:
the method has the following advantages: the corresponding discomfort symptoms of the patient are eliminated or reduced. Such as: the patients have no dizziness, headache, head distension, chest distress and chest pain feeling, or the degree is obviously improved; the related indexes of blood pressure, blood viscosity, blood fat and the like are normal, the daily life of the food is normal, and the self-care ability of life is obviously enhanced.
No effect, and no improvement in all aspects of the patients compared to before drug treatment.
The clinical case observation of patients who adopt the pharmaceutical composition to treat diseases or symptoms such as coronary heart disease, arteriosclerosis, palpitation, syndrome X, perimenopausal syndrome and the like is carried out to further explain the curative effect of the pharmaceutical composition of the invention:
case one: liu Jie, male, age 44, will be diagnosed in 2020, 1 month. Chest distress and chest pain occur in 2 years, the activity endurance is reduced, the chest distress and short breath are caused by slight movement, the patient is sleepy and does not move in normal times, cough and sputum are caused in the morning, and the patient has dizziness, poor spirit and loose stool. The method is characterized in that the hypertension, the mild fatty liver and the blood fat (cholesterol 6.6, LDL _ C4.64) are not high in the hospitalization of an external hospital, the coronary angiography examination shows that the coronary heart disease double-branch lesion (the middle-section stenosis of the right crown is 50% -60%, the middle-section stenosis of the anterior descending branch is 50%) is observed, rosuvastatin and aspirin are taken for 3 months, the symptoms are not improved for diagnosis, the traditional Chinese medicine is required to be taken, and after the pill (the pill of the pharmaceutical composition for treating the cardiovascular and cerebrovascular diseases) is decocted with water for 1 month, the symptoms are obviously reduced, the pill is taken for 3 months, and all the symptoms are eliminated. After that, the pill is taken every month for 2 weeks, and the disease condition is stable. In the last 1 year, chest distress and chest pain do not occur.
In case two, Wangzhenyu, women, 74 years old, Hunan, followed by children, Shenzhen for many years, often manifested as dizziness and chest stuffiness, and activities often induce chest stuffiness and pain. Hypertension was found in 2012, and was confirmed to be coronary heart disease, proximal stenosis of right coronary 70%, anterior descending and circumflex stenosis 30% -50% in 2018. Usually, dizziness and heaviness of the head often cause chest stuffiness and shortness of breath, frequent chest stuffiness and pain in activity or excitement, bitter taste and dry mouth, sticky and greasy mouth, bad appetite, abdominal distension, loose stool, purple and dark tongue, tooth marks on the tongue edge, white, thick and greasy tongue coating and wiry and smooth pulse. The pill is orally taken for 5 months, the upper symptoms are obviously reduced, and the pill is taken for 2 weeks every month, so the condition is stable. In 2021, coronary angiography at 3 months reduced 70% of the original proximal coronary stenosis to about 50%, and 30% of the anterior descending and circumflex stenosis.
In case three, hypertension was found in Huang-Shi, male, 72 years old, 1988, and nitrendipine tablets were taken 3 times a day to control blood pressure; chest distress and pain appear in 1990, and are diagnosed as coronary heart disease and angina, and after taking the tablets, atorvastatin and isosorbide dinitrate for a long time, the patients still have chest distress, similar to blockage, short breath, heavy dizziness and seek to me, and the traditional Chinese medicine is required. Checking: dark red tongue with white and greasy coating and soft pulse. After 3 weeks of traditional Chinese medicine regulation, the pill is changed into a pill with the advantages of red sage root, fragrant solomonseal rhizome and blood circulation promoting, and the disease condition is stable after long-term administration for more than 20 years.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the scope of the present invention, and all equivalent modifications made by the present invention in the light of the present specification, or directly/indirectly applied to other related technical fields are included in the scope of the present invention.

Claims (10)

1. The medicine composition for treating the cardiovascular and cerebrovascular diseases is characterized by being a medicament prepared from nine traditional Chinese medicines, namely, salvia miltiorrhiza, fructus amomi, agilawood, trichosanthes kirilowii maxim, allium macrostemon, rhizoma pinellinae praeparata, immature bitter orange, rhodiola rosea and pseudo-ginseng, wherein the traditional Chinese medicines comprise the following components in parts by weight: 10-40 parts of salvia miltiorrhiza, 5-20 parts of fructus amomi, 5-20 parts of agilawood, 15-60 parts of snakegourd fruit, 5-20 parts of allium macrostemon, 5-20 parts of rhizoma pinellinae praeparata, 5-20 parts of immature bitter orange, 5-20 parts of rhodiola rosea and 5-20 parts of pseudo-ginseng.
2. The pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to claim 1, wherein the ratio of each traditional Chinese medicine by weight portion is: 20-35 parts of salvia miltiorrhiza, 8-15 parts of fructus amomi, 8-15 parts of agilawood, 25-45 parts of snakegourd fruit, 8-15 parts of allium macrostemon, 8-15 parts of rhizoma pinellinae praeparata, 8-15 parts of immature bitter orange, 8-15 parts of rhodiola rosea and 8-15 parts of pseudo-ginseng.
3. The pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to claim 1, wherein the optimal mixture ratio of each Chinese medicine by weight portion is: 25 parts of salvia miltiorrhiza, 12 parts of fructus amomi, 12 parts of agilawood, 37 parts of snakegourd fruit, 12 parts of allium macrostemon, 12 parts of rhizoma pinellinae praeparata, 10 parts of immature bitter orange, 10 parts of rhodiola rosea and 11 parts of pseudo-ginseng.
4. The pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to any one of claims 1 to 3, wherein the weight parts are weight units of gram, two, jin or kg.
5. The pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to claim 4, wherein the dosage form of the pharmaceutical composition is pill or powder.
6. The pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to claim 4, wherein the dosage form of the pharmaceutical composition is pellet, tablet, granule or capsule.
7. A method for preparing the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to claim 5, wherein the method comprises:
(1) weighing the nine traditional Chinese medicines in parts by weight;
(2) cleaning the nine traditional Chinese medicines, removing impurities, drying, mixing, crushing, sieving, sterilizing, forming pills or powder and packaging to form the pills or powder of the pharmaceutical composition.
8. A preparation method for preparing the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to claim 6, wherein the preparation method comprises the following steps:
(1) weighing the nine traditional Chinese medicines in parts by weight;
(2) cleaning, slicing and mixing the nine traditional Chinese medicines, adding water into the mixed nine traditional Chinese medicines, and adding 1120-2000 parts by weight of purified water;
(3) decocting the nine traditional Chinese medicines with water, decocting with big fire for 20-60 minutes, decocting with small fire for 20-60 minutes, filtering to remove residues, decocting the residues with 610-1100 parts by weight of pure water for 30-90 minutes, filtering to remove residues; mixing the first and second medicinal liquids, adding conventional adjuvants, and making into clinically acceptable oral liquid, tablet, granule, pill or capsule.
9. The use method of the pharmaceutical composition for treating cardiovascular and cerebrovascular diseases according to claim 5, wherein the use method comprises:
after the pharmaceutical composition is formed into pills or powder, the pharmaceutical composition is orally taken for 2-3 times a day, and 8g to 10g of the pharmaceutical composition is orally taken each time.
10. Use of a pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases according to any one of claims 1 to 6, for the prevention and treatment of coronary heart disease, arteriosclerosis, palpitation, syndrome X, perimenopausal syndrome.
CN202110477676.XA 2021-04-29 2021-04-29 Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application Pending CN113274471A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110477676.XA CN113274471A (en) 2021-04-29 2021-04-29 Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110477676.XA CN113274471A (en) 2021-04-29 2021-04-29 Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application

Publications (1)

Publication Number Publication Date
CN113274471A true CN113274471A (en) 2021-08-20

Family

ID=77277768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110477676.XA Pending CN113274471A (en) 2021-04-29 2021-04-29 Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application

Country Status (1)

Country Link
CN (1) CN113274471A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116870121A (en) * 2023-08-18 2023-10-13 北京中医药大学东方医院 Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张维维等: ""天香通脉丸联合美托洛尔缓释片治疗冠心病心绞痛的效果及对血液流变学指标的影响"", 《海峡药学》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116870121A (en) * 2023-08-18 2023-10-13 北京中医药大学东方医院 Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof
CN116870121B (en) * 2023-08-18 2024-04-02 北京中医药大学东方医院 Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof

Similar Documents

Publication Publication Date Title
CN1895620A (en) Chinese-medicinal composition for treating coronary heart disease
CN102210835B (en) Traditional Chinese medicine for treating coronary disease
CN113274471A (en) Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application
CN106474356A (en) A kind of medicine of logical stalkization bolt and preparation method thereof
CN102178798A (en) Preparation for reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases
CN102406743B (en) Traditional Chinese preparation for treating cerebral thrombosis
CN115252753A (en) Traditional Chinese medicine composition for treating insomnia and application thereof
CN101450189B (en) Medicine for curing angiocardiopathy and cerebrovascular disease and its preparing method
CN114949122A (en) Traditional Chinese medicine composition for treating blood stasis-yang hyperactivity-phlegm turbidity syndrome hypertension and application thereof
CN112089784A (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis
CN115089676B (en) Application of swertia mileensis-containing traditional Chinese medicine compound composition in preparation of secondary prevention medicine for treating coronary heart disease
CN110548099A (en) Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method thereof
CN113144080B (en) Traditional Chinese medicine for treating coronary atherosclerotic plaques
CN108743885A (en) A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications
CN115006492B (en) Traditional Chinese medicine composition for treating insomnia and application thereof
CN114306497B (en) Traditional Chinese medicine composition for treating kidney deficiency and blood stasis type osteoporosis, preparation and application
CN112089783B (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity
CN113413445B (en) Composition and preparation method and application thereof
CN114272329B (en) Traditional Chinese medicine composition for treating liver and kidney deficiency type cervical spondylosis, preparation and application
CN102755444A (en) Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof
CN118001362A (en) Traditional Chinese medicine composition, preparation and application for treating qi deficiency and blood stasis type coronary heart disease angina or PCI postoperative angina
CN105832934A (en) Traditional Chinese medicine for treating hypertension
CN116077611A (en) Traditional Chinese medicine compound with yang warming and heart benefiting effects
CN105267470B (en) Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease
CN103356984B (en) Traditional Chinese medicine composition for preventing and treating female iron deficiency anemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210820

RJ01 Rejection of invention patent application after publication